Because of this, a number of studies have been conducted to address the question of whether cardiovascular diseases can be modulated by antioxidant treatment or consumption.
This raises the question of how cardiovascular tubes form in invertebrates?
The single most important issue to be addressed in this research field is the question of patients' cardiovascular outcomes on GLP-1R agonist therapy.
Lastly, we addressed the question of whether cardiovascular abnormalities could be the primary cause of respiratory distress and cyanosis in KLEIP −/− mice as has been described for Foxc2- and Sema3c-deficient single-mutant mice (Feiner et al., 2001; Iida et al., 1997).
This new triage tool was developed to guide the nurse's decision and was based on three key questions: presence of cardiovascular risk factors, previous atherosclerotic disease (coronary artery disease, stroke, peripheral arterial disease, carotid stenosis, aortic aneurysms, renal artery stenosis), and symptoms on admission.
Questions on indication of cardiovascular medication and breathlessness were lacking at the start of the Rotterdam Study, but have subsequently been added.
According to participants' responses to the corresponding questions, family history of cardiovascular disease (CVD) or diabetes was classified as yes or no.
Phillip Home (Newcastle, U.K). addressed the question of PPARγ agonist cardiovascular (CV) effects by asking, "Has the dust settled?
The existence of a national prescription database with comprehensive recording of all prescriptions filled in Denmark since 1995, with the possibility of linkage to a wide array of other health databases (6), offered us a unique opportunity to address the question of ephedrine's cardiovascular toxicity in a controlled observational study.
Since a positive family history doubles the future risk, a question on family history of cardiovascular disease was added [ 8].
